



## Curriculum Vitae

### Personal information Antonello Di Paolo

#### Work experience

---

February 2023 - present: Pharmacologist, Phase I Clinical Trial Unit, Civil Hospital, Ravenna, Italy - Evaluation of risks of Phase I clinical trials in oncology and hematology

November 2017 - present: President and Scientific member, Animal Welfare Body, University of Pisa, Pisa, Italy - As President, coordination of AWB activities and training courses on the protection of animals used for scientific purposes. As scientific member, evaluation of preclinical study protocols according to European and Italian law.

February 2017 - present: Pharmacologist, Phase I Clinical Trial Unit, IRCCS IRST Meldola, Forlì, Italy - Evaluation of risks of Phase I clinical trials in oncology and hematology

January 1, 2016 - present: member, Patent Commission, University of Pisa, Pisa, Italy - Evaluation of medical and pharmaceutical patents

December 29, 2014 - present: Associate Professor of Pharmacology, University of Pisa, Pisa, Italy - Research and teaching activities in the area of preclinical and clinical pharmacology and pharmacokinetics, with special interest in anti-infective and anti-neoplastic chemotherapy

August 2010 - June 2014: Pharmacologist, Ethics Committee, Civil Hospital, Livorno, Italy. Evaluation of sponsored and no-profit protocols

April 1, 2002 - present: Physician, Unit of Clinical Pharmacology and Pharmacogenetics, University Hospital, Pisa, Italy - Therapeutic drug monitoring and pharmacogenetic analyses

#### Education and training

---

May 2011: Sabbatical, Dept. Pharmaceutical Biosciences, Uppsala Sweden - Population Pharmacokinetics of antimicrobial drugs

January - February 2008: Sabbatical, Molecular Pharmacology Branch, NIH, Bethesda, MD - Pharmacogenetic studies in prostate cancer patients

September - November 2003: CNR-NATO Fellowship, Yale University Medical School, New Haven, CT - Dihydropyrimidine dehydrogenase: *in vitro* studies

November 2000 - May 2001: Biennial research grant, University of Pisa - Dihydropyrimidine dehydrogenase in colorectal cancer patients

November 1996 - October 2000: Resident in Pharmacology and Clinical Toxicology, University of Pisa

November 1992 - October 1995: PhD fellow, Sant'Anna School of Advanced Studies, Pisa - Preclinical and clinical pharmacology of anticancer drugs

October 1986 - October 1992: undergraduate student, Section of Medicine, Experimental Science Dept., Sant'Anna School of Advanced Studies, Pisa and Faculty of Medicine, University of Pisa

#### Additional information

---

##### Publications

ORCID ID: 0000-0002-2661-6183

Web of Science Researcher ID: K-1413-2018

- Maximova N, Calabrò PF, Cangialosi A, Di Paolo A. Therapeutic drug monitoring, population pharmacokinetics models and external validation of high-dose methotrexate in pediatric acute lymphoblastic leukemia. *Chemotherapy* 2024, in press, DOI:10.1159/000543181
- Braidotti S, Curci D, Maestro A, Zanon D, Maximova N, Di Paolo A. Effect of early post-hematopoietic stem cell transplant tacrolimus concentration on transplant outcomes in pediatric recipients: One facility's ten-year experience of immunosuppression with tacrolimus. *Int Immunopharmacol.* 2024

Sep 10;138:112636. doi: 10.1016/j.intimp.2024.112636. Epub 2024 Jul 10. PMID: 38991629.

- Le Teuff G, Cozic N, Boyer JC, Boige V, Diasio RB, Taieb J, Meulendijks D, Palles C, Schwab M, Deenen M, Largiadèr CR, Marinaki A, Jennings BA, Wettergren Y, Di Paolo A, Gross E, Budai B, Ackland SP, van Kuilenburg ABP, McLeod HL, Milano G, Thomas F, Lorient MA, Kerr D, Schellens JHM, Laurent-Puig P, Shi Q, Pignon JP, Etienne-Grimaldi MC; FUSAFE collaborative group. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. *Br J Cancer*. 2024 Mar;130(5):808-818. doi: 10.1038/s41416-023-02517-2. Epub 2024 Jan 15. PMID: 38225422; PMCID: PMC10912560.
- Galimberti S, Abruzzese E, Luci G, Baratè C, Luciano L, Iurlo A, Caocci G, Morganti R, Stefanelli F, Di Paolo A. A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia. *Pharmaceutics*. 2024 Mar 11;16(3):383. doi: 10.3390/pharmaceutics16030383. PMID: 38543276; PMCID: PMC10975223.
- Fulvio G, Baldini C, Mosca M, di Paolo A, Bocci G, Palumbo GA, Cacciola E, Migliorini P, Cacciola R, Galimberti S. Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations? *Front Med (Lausanne)*. 2023 Oct 17;10:1254868. doi: 10.3389/fmed.2023.1254868. PMID: 37915324; PMCID: PMC10616863.
- Ferrero S, Grimaldi D, Arrigoni E, Pironti M, Zaccaria GM, Alessandria B, Genuardi E, De Luca G, Ghislieri M, Tavarozzi R, Di Rocco A, Re A, Stefoni V, Cavallo F, Boccomini C, Balzarotti M, Zilioli V, Moita F, Arcaini L, Lucchini E, Ballerini F, Ferreri AJM, Puccini B, Palumbo GA, Galimberti S, Cortelazzo S, Di Paolo A, Ladetto M. Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. *Blood Adv*. 2023 Jul 25;7(14):3764-3774. doi: 10.1182/bloodadvances.2022009504. PMID: 37058477; PMCID: PMC10368781.
- Mandelli G, Dore F, Langer M, Garbero E, Alagna L, Bianchin A, Ciceri R, Di Paolo A, Giani T, Giugni A, Gori A, Lefons U, Muscatello A, Olivieri C, Pan A, Pedferri M, Rossi M, Rossolini GM, Russo E, Silengo D, Viaggi B, Bertolini G, Finazzi S. Effectiveness of a Multifaced Antibiotic Stewardship Program: A Pre-Post Study in Seven Italian ICUs. *J Clin Med*. 2022 Jul 28;11(15):4409. doi: 10.3390/jcm11154409. PMID: 35956026; PMCID: PMC9369193.
- Balice G, Passino C, Bongiorno MG, Segreti L, Russo A, Lastella M, Luci G, Falcone M, Di Paolo A. Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update. *Antibiotics (Basel)*. 2022 Jul 7;11(7):914. doi: 10.3390/antibiotics11070914. PMID: 35884168; PMCID: PMC9311615.
- Cucchiara F, Luci G, Giannini N, Giorgi FS, Orlandi P, Banchi M,

- Di Paolo A, Pasqualetti F, Danesi R, Bocci G. Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. *Pharmacol Res.* 2022 Jul;181:106290. doi: 10.1016/j.phrs.2022.106290. Epub 2022 Jun 6. PMID: 35680010.
- Maximova N, Nisticò D, Luci G, Simeone R, Piscianz E, Segat L, Barbi E, Di Paolo A. Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients. *Front Pharmacol.* 2022 Apr 14;13:865871. doi: 10.3389/fphar.2022.865871. PMID: 35496277; PMCID: PMC9050193.
  - Abruzzese E, Aureli S, Bondanini F, Ciccarone M, Cortis E, Di Paolo A, Fabiani C, Galimberti S, Malagola M, Malato A, Martino B, Trawinska MM, Russo D, de Fabritiis P. Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. *J Clin Med.* 2022 Mar 24;11(7):1801. doi: 10.3390/jcm11071801. PMID: 35407407; PMCID: PMC8999799.
  - Galeotti L, Ceccherini F, Fucile C, Marini V, Di Paolo A, Maximova N, Mattioli F. Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients. *Pharmaceutics.* 2021 Aug 11;13(8):1238. doi: 10.3390/pharmaceutics13081238. PMID: 34452199; PMCID: PMC8401444.
  - Loscocco F, Visani G, Ruzzo A, Bagaloni I, Fuligni F, Galimberti S, Di Paolo A, Stagno F, Pregno P, Annunziata M, Gozzini A, Barulli S, Gabucci E, Magnani M, Isidori A. Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. *Front Oncol.* 2021 May 13;11:672287. doi: 10.3389/fonc.2021.672287. PMID: 34055641; PMCID: PMC8155509.
  - Galimberti S, Baldini C, Baratè C, Fornili M, Balducci S, Ricci F, Ferro F, Elefante E, Di Paolo A, Baglietto L, Donati V, Petrini M. Myeloid neoplasms and autoimmune diseases: markers of association. *Clin Exp Rheumatol.* 2022 Jan;40(1):49-55. doi: 10.55563/clinexprheumatol/ddxmp9. Epub 2021 Jan 6. PMID: 33427624.
  - Falcone M, Menichetti F, Cattaneo D, Tiseo G, Baldelli S, Galfo V, Leonildi A, Tagliaferri E, Di Paolo A, Pai MP. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. *J Antimicrob Chemother.* 2021 Mar 12;76(4):1025-1031. doi: 10.1093/jac/dkaa549. PMID: 33378458; PMCID: PMC8861369.
  - Di Paolo A, Cremolini C, Bocci G. Universal Pretreatment *DPYD* Genotyping in Fluoropyrimidine Candidates: Still Controversial but With Clear Instructions for Practitioners, at Last! *JCO Oncol Pract.* 2020 Dec;16(12):801-802. doi: 10.1200/OP.20.00903. PMID: 33301696.
  - Lapucci A, Perrone G, Di Paolo A, Napoli C, Landini I, Roviello G, Calosi L, Naccarato AG, Falcone A, Bani D, Mini E, Nobili S. *PNN* and *KCNQ1OT1* Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. *Oncol Res.* 2021 Mar 16;28(6):631-644. doi:

10.3727/096504020X16056983169118. Epub 2020 Nov 18.  
PMID: 33208224; PMCID: PMC7962934.

- Galimberti S, Petrini M, Baratè C, Ricci F, Balducci S, Grassi S, Guerrini F, Ciabatti E, Mechelli S, Di Paolo A, Baldini C, Baglietto L, Macera L, Spezia PG, Maggi F. Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. *Front Oncol.* 2020 Sep 2;10:1428. doi: 10.3389/fonc.2020.01428. PMID: 33014780; PMCID: PMC7493657.
- Grassi S, Palumbo S, Mariotti V, Liberati D, Guerrini F, Ciabatti E, Salehzadeh S, Baratè C, Balducci S, Ricci F, Buda G, Iovino L, Mazziotta F, Ghio F, Ercolano G, Di Paolo A, Cecchetti A, Baldini C, Mattii L, Pellegrini S, Petrini M, Galimberti S. The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. *Front Oncol.* 2019 Jun 24;9:532. doi: 10.3389/fonc.2019.00532. PMID: 31293972; PMCID: PMC6601352.
- Sarli V, Ciofi L, Lastella M, Muscatello B, Pisaturo F, Paolilli O, Luci G, Cucchiara F, Pellegrini G, Bocci G, Danesi R, Di Paolo A. Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time. *Clin Chem Lab Med.* 2019 Nov 26;57(12):e331-e333. doi: 10.1515/cclm-2019-0429. PMID: 31188753.
- Di Paolo A, Ciofi L, Bacca A, Bernini G. A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment. *J Chemother.* 2019 Apr;31(2):105-108. doi: 10.1080/1120009X.2018.1552502. Epub 2019 Mar 4. PMID: 30831058.
- Masi G, Vivaldi C, Fornaro L, Lonardi S, Bucciante P, Sainato A, Marcucci L, Martignetti A, Luca Urso ED, Castagna M, Fontanini G, Bergamo F, Musettini G, Urbani L, Sensi E, Balestri R, Montrone S, Pasqualetti F, Cremolini C, Di Paolo A, Zagonel V, Falcone A. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. *Eur J Cancer.* 2019 Mar;110:32-41. doi: 10.1016/j.ejca.2019.01.006. Epub 2019 Feb 7. PMID: 30739838.
- Piva S, Di Paolo A, Galeotti L, Ceccherini F, Cordoni F, Signorini L, Togni T, De Nicolò A, Rasulo FA, Fagoni N, Latronico N, D'Avolio A. Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. *Neurocrit Care.* 2019 Aug;31(1):116-124. doi: 10.1007/s12028-018-0657-y. PMID: 30607829.
- Galimberti S, Grassi S, Baratè C, Guerrini F, Ciabatti E, Perutelli F, Ricci F, Del Genio G, Montali M, Barachini S, Giuliani C, Ferreri MI, Valetto A, Abruzzese E, Ippolito C, Iurlo A, Bocchia M, Sicuranza A, Martino B, Iovino L, Buda G, Salehzadeh S, Petrini M, Di Paolo A, Mattii L. The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. *Front Oncol.* 2018 Dec 6;8:555. doi: 10.3389/fonc.2018.00555. PMID: 30574454; PMCID:

PMC6291509.

- Scatena C, Roncella M, Di Paolo A, Aretini P, Menicagli M, Fanelli G, Marini C, Mazzanti CM, Ghilli M, Sotgia F, Lisanti MP, Naccarato AG. Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study. *Front Oncol.* 2018 Oct 12;8:452. doi: 10.3389/fonc.2018.00452. PMID: 30364293; PMCID: PMC6194352.
- Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, D'Avolio A. A Common *mdr1* Gene Polymorphism is Associated With Changes in Linezolid Clearance. *Ther Drug Monit.* 2018 Oct;40(5):602-609. doi: 10.1097/FTD.0000000000000536. PMID: 29979333.
- Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. The *hOCT1* and *ABCB1* polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. *Oncotarget.* 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. PMID: 29152138; PMCID: PMC5675690.
- Di Paolo A, Sarkozy F, Ryll B, Siebert U. Personalized medicine in Europe: not yet personal enough? *BMC Health Serv Res.* 2017 Apr 19;17(1):289. doi: 10.1186/s12913-017-2205-4. PMID: 28424057; PMCID: PMC5395930.
- Galeotti L, Ceccherini F, Domingo D, Laurino M, Polillo M, Di Paolo A, Baratè C, Fava C, D'Avolio A, Cervetti G, Guerrini F, Fontanelli G, Ciabatti E, Grassi S, Arrigoni E, Danesi R, Petrini M, Cornolti F, Saglio G, Galimberti S. Association of the *hOCT1/ABCB1* genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. *Cancer Chemother Pharmacol.* 2017 Apr;79(4):767-773. doi: 10.1007/s00280-017-3271-3. Epub 2017 Mar 13. PMID: 28289867.
- Di Paolo A, Orlandi P, Di Desidero T, Danesi R, Bocci G. Simultaneous, But Not Consecutive, Combination With Folate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo. *Oncol Res.* 2017 Aug 7;25(7):1129-1140. doi: 10.3727/096504017X14841698396900. Epub 2017 Jan 20. PMID: 28109077; PMCID: PMC7841196.
- Mattioli F, Fucile C, Del Bono V, Marini V, Parisini A, Molin A, Zuccoli ML, Milano G, Danesi R, Marchese A, Polillo M, Viscoli C, Pelosi P, Martelli A, Di Paolo A. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. *Eur J Clin Pharmacol.* 2016 Jul;72(7):839-48. doi: 10.1007/s00228-016-2053-x. Epub 2016 Apr 6. PMID: 27048201.
- Crea F, Di Paolo A, Liu HH, Polillo M, Clermont PL, Guerrini F, Ciabatti E, Ricci F, Baratè C, Fontanelli G, Barsotti S, Morganti R, Danesi R, Wang Y, Petrini M, Galimberti S, Helgason CD.

Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. *Epigenomics*. 2015 Aug;7(5):757-65. doi: 10.2217/epi.15.35. Epub 2015 Sep 7. PMID: 26343356; PMCID: PMC5551942.

- Carulli G, Baratè C, Marini A, Ottaviano V, Cervetti G, Fontanelli G, Guerrini F, Arici R, Guerri V, Di Paolo A, Polillo M, Ferreri MI, Galimberti S, Petrini M. Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib. *Hematol Oncol*. 2015 Dec;33(4):250-2. doi: 10.1002/hon.2156. Epub 2014 Sep 25. PMID: 25256816.
- Di Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. *Clin Infect Dis*. 2014 Jun;58(12):1788-9. doi: 10.1093/cid/ciu230. Epub 2014 Apr 11. PMID: 24729499.
- Di Paolo A, Polillo M, Capecchi M, Cervetti G, Baratè C, Angelini S, Guerrini F, Fontanelli G, Arici R, Ciabatti E, Grassi S, Bocci G, Hrelia P, Danesi R, Petrini M, Galimberti S. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. *Pharmacogenomics J*. 2014 Aug;14(4):328-35. doi: 10.1038/tpj.2014.7. Epub 2014 Mar 4. PMID: 24589908.
- Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, Di Paolo A, Ripoli A, Lewis R, Rossolini GM, Menichetti F; GENGUT Study Group. Oral gentamicin gut decontamination for prevention of KPC-producing *Klebsiella pneumoniae* infections: relevance of concomitant systemic antibiotic therapy. *Antimicrob Agents Chemother*. 2014;58(4):1972-6. doi: 10.1128/AAC.02283-13. Epub 2014 Jan 13. PMID: 24419337; PMCID: PMC4023775.
- Di Paolo A, Tascini C, Polillo M, Gemignani G, Nielsen EI, Bocci G, Karlsson MO, Menichetti F, Danesi R. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. *Int J Antimicrob Agents*. 2013 Sep;42(3):250-5. doi: 10.1016/j.ijantimicag.2013.06.006. Epub 2013 Jul 25. PMID: 23891432.
- Tascini C, Di Paolo A, Poletti R, Flammini S, Emdin M, Ciullo I, Tagliaferri E, Moter A, Menichetti F. Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis. *Antimicrob Agents Chemother*. 2013 Jan;57(1):601-2. doi: 10.1128/AAC.01608-12. Epub 2012 Oct 22. PMID: 23089753; PMCID: PMC3535905.
- Woloch C, Di Paolo A, Marouani H, Bocci G, Ciccolini J, Lacarelle B, Danesi R, Iliadis A. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. *Curr Top Med Chem*. 2012;12(15):1713-9. doi: 10.2174/156802612803531414. PMID: 22978343.
- Brandi G, Biasco G, Mirarchi MG, Golfieri R, Di Paolo A, Borghi A, Fanello S, Derenzini E, Agostini V, Giampalma E, Cappelli A, Pini P, Costantini S, Danesi R, Bolondi L, Piscaglia F. A phase I

study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. *Dig Liver Dis.* 2011 Dec;43(12):1015-21. doi: 10.1016/j.dld.2011.08.005. Epub 2011 Sep 13. PMID: 21917536.

- Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. *Br J Cancer.* 2011 Apr 12;104(8):1262-9. doi: 10.1038/bjc.2011.85. Epub 2011 Mar 15. PMID: 21407216; PMCID: PMC3078596.
- Ibrahim T, Di Paolo A, Amatori F, Mercatali L, Ravaioli E, Flamini E, Sacanna E, Del Tacca M, Danesi R, Amadori D. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. *J Clin Pharmacol.* 2012 Mar;52(3):361-9. doi: 10.1177/0091270010396710. Epub 2011 Mar 7. PMID: 21383342.
- Sbrana F, Di Paolo A, Pasanisi EM, Tagliaferri E, Arvia C, Puntoni M, Leonildi A, Bigazzi F, Danesi R, Rovai D, Tascini C, Menichetti F. Administration interval and daptomycin toxicity: a case report of rhabdomyolysis. *J Chemother.* 2010 Dec;22(6):434-5. doi: 10.1179/joc.2010.22.6.434. PMID: 21303756.
- Consoli G, Lastella M, Ciapparelli A, Catena Dell'Osso M, Ciofi L, Guidotti E, Danesi R, Dell'Osso L, Del Tacca M, Di Paolo A. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. *Pharmacogenomics.* 2009 Aug;10(8):1267-76. doi: 10.2217/pgs.09.51. PMID: 19663671.
- Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, Loupakis F, Allegrini G, Falcone A, Del Tacca M, Danesi R. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. *Br J Clin Pharmacol.* 2009 Jan;67(1):132-4. doi: 10.1111/j.1365-2125.2008.03307.x. Epub 2008 Nov 5. PMID: 19006547; PMCID: PMC2668095.
- Fornaro L, Masi G, Bursi S, Loupakis F, Vasile E, Antonuzzo A, Chiara S, Pfanner E, Di Paolo A, Bocci G, Del Tacca M, Falcone A. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. *Cancer Chemother Pharmacol.* 2009 Apr;63(5):965-9. doi: 10.1007/s00280-008-0840-5. Epub 2008 Oct 7. PMID: 18839174.
- Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, Ricci S, Del Tacca M, Danesi R. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. *Clin Cancer Res.* 2008 May 1;14(9):2749-55. doi: 10.1158/1078-0432.CCR-07-1529. PMID: 18451241.
- Amatori F, Di Paolo A, Del Tacca M, Fontanini G, Vannozzi F, Boldrini L, Bocci G, Lastella M, Danesi R. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. *Pharmacogenet Genomics.* 2006 Nov;16(11):809-16. doi:

- 10.1097/01.fpc.0000230410.07899.bc. PMID: 17047489.
- Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. *Clin Pharmacol Ther.* 2006 Oct;80(4):384-95. doi: 10.1016/j.clpt.2006.06.007. PMID: 17015056.
  - Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. *Cancer Chemother Pharmacol.* 2006 Nov;58(5):585-93. doi: 10.1007/s00280-006-0205-x. Epub 2006 May 6. PMID: 16680463.
  - Di Paolo A, Danesi R, Ciofi L, Vannozzi F, Bocci G, Lastella M, Amatori F, Martelloni BM, Ibrahim T, Amadori D, Falcone A, Del Tacca M. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. *Ther Drug Monit.* 2005 Jun;27(3):362-8. doi: 10.1097/01.ftd.0000162016.11148.1b. PMID: 15905808.
  - Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. *Transplant Proc.* 2004 Nov;36(9):2787-90. doi: 10.1016/j.transproceed.2004.09.070. PMID: 15621150.
  - Masi G, Falcone A, Di Paolo A, Allegrini G, Danesi R, Barbara C, Cupini S, Del Tacca M. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. *Clin Cancer Res.* 2004 Mar 1;10(5):1657-63. doi: 10.1158/1078-0432.ccr-1585-3. PMID: 15014016.
  - Bocci G, Danesi R, Allegrini G, Innocenti F, Di Paolo A, Falcone A, Conte PF, Del Tacca M. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. *Eur J Clin Pharmacol.* 2002 Dec;58(9):593-5. doi: 10.1007/s00228-002-0534-6. PMID: 12602342.
  - Di Paolo A, Danesi R, Vannozzi F, Falcone A, Mini E, Cionini L, Ibrahim T, Amadori D, Del Tacca M. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. *Clin Pharmacol Ther.* 2002 Dec;72(6):627-37. doi: 10.1067/mcp.2002.128867. PMID: 12496744.
  - Di Paolo A, Barbara C, Chella A, Angeletti CA, Del Tacca M. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. *Pharmacol Res.* 2002 Dec;46(6):545-50. doi: 10.1016/s1043661802002384. PMID: 12457629.
  - Di Paolo A, Ibrahim T, Danesi R, Maltoni M, Vannozzi F, Flamini E, Zoli W, Amadori D, Del Tacca M. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and

- toxicity of 5-fluorouracil infusions in cancer patients. *Ther Drug Monit.* 2002 Oct;24(5):588-93. doi: 10.1097/00007691-200210000-00002. PMID: 12352929.
- Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. *J Clin Oncol.* 2002 Oct 1;20(19):4006-14. doi: 10.1200/JCO.2002.12.075. PMID: 12351598.
  - Danesi R, Innocenti F, Fogli S, Gennari A, Baldini E, Di Paolo A, Salvadori B, Bocci G, Conte PF, Del Tacca M. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. *Br J Clin Pharmacol.* 2002 May;53(5):508-18. doi: 10.1046/j.1365-2125.2002.01579.x. PMID: 11994057; PMCID: PMC1874362.
  - Blandizzi C, Danesi R, De Paolis B, Di Paolo A, Colucci R, Falcone A, Del Tacca M. Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. *Clin Pharmacol Ther.* 2002 Apr;71(4):263-71. doi: 10.1067/mcp.2002.121909. PMID: 11956509.
  - Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. *Ann Oncol.* 2001 Sep;12(9):1301-6. doi: 10.1023/a:1012294617392. PMID: 11697844.
  - Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. *J Clin Oncol.* 2001 Aug 1;19(15):3456-62. doi: 10.1200/JCO.2001.19.15.3456. PMID: 11481350.
  - Di Paolo A, Danesi R, Caputo S, Macchia M, Lastella M, Boggi U, Mosca F, Marchetti A, Del Tacca M. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. *Br J Cancer.* 2001 Jun 1;84(11):1535-43. doi: 10.1054/bjoc.2001.1820. PMID: 11384105; PMCID: PMC2363657.
  - Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. *Clin Cancer Res.* 2000 Aug;6(8):3032-7. PMID: 10955781.
  - Di Paolo A, Danesi R, Nardini D, Bocci G, Innocenti F, Fogli S, Barachini S, Marchetti A, Bevilacqua G, Del Tacca M. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. *Br J Cancer.* 2000 Feb;82(4):905-12. doi: 10.1054/bjoc.1999.1018. PMID: 10732765; PMCID: PMC2374379.

## Projects

The projects listed below are aimed at investigating possible pharmacogenetic (germline) determinants to predict treatment efficacy and tolerability and to investigate factors associated with alterations in drug pharmacokinetics.

### Oncology and Hematology Area

- Pharmacogenetics in follicular lymphoma: a pharmacogenetic substudy of FOLL012 protocol, Fondazione Italiana Linfomi
- Pharmacogenetics in mantle cell lymphoma: a substudy of MCL0208 protocol, Fondazione Italiana Linfomi.
- Tyrosine kinase inhibitors in Chronic myeloid Leukemia: therapeutic drug monitoring, pharmacogenetics and pharmacokinetics
- High-dose Methotrexate in children: population pharmacokinetics
- DPYD polymorphisms and treatment tolerability

### Infectious Disease area

- Antibacterial drugs for severe infections
- Maintenance oral acyclovir in children who received HSCT
- Anti-CMV drugs in children receiving HSCT

### Patent

- WO 2022/112965 A2: Method implemented by means of a computer for determining retention times and concentration values of analytes in a mixture

## Memberships

### Memberships

- 1997-present: Member of Italian Society of Pharmacology (SIF) and the SIF Clinical Pharmacology Section
- 1999-present: Italian Society of Chemotherapy
- 2001-2020: American Association for Cancer Research
- 2018-present: Italian Society of Clinical Biochemistry and Clinical molecular Biology

## Other Relevant Information

### Main areas of interest

- Pharmacokinetics (PK) of chemical drugs, small molecules and monoclonal antibodies, PK analysis and population PK in order to identify factors associated with inter- and intra-individual variability in drug disposition in preclinical studies and clinical trials;

- Pharmacogenetics (PGx) of antineoplastic drugs: evaluation of allelic variants in genes coding for proteins involved in drug PK and activity in clinical trials.